Introduction
Breast cancer remains a leading driver of global oncology mortality, primarily due to distant
metastasis and therapeutic resistance [Borst et al., 2026; Taylor et al., 2024]. Among molecular
profiles, hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-
negative (HER2−) disease represents over two-thirds of all new diagnoses [Taylor et al., 2024].
Historically, clinical management relied on conventional clinicopathological parameters—such
as patient age, tumor size, histologic grade, and lymph node status—to estimate recurrence risk
and prescribe empiric adjuvant chemotherapy [Sinn et al., 2013; Siegelmann-Danieli et al., 2013;
Taylor et al., 2024]. However, this uniform approach failed to capture the profound biological
variability inherent within breast cancer subtypes, leading to widespread clinical overtreatment
of low-risk patients and under-treatment of aggressive tumors [Borst et al., 2026; Taylor et al.,
2024].
To optimize risk stratification, modern oncology has integrated commercial multigene profiling
assays, including Oncotype DX, MammaPrint, Prosigna, and EndoPredict [Borst et al., 2026;
Nalbant et al., 2025; Sinn et al., 2013]. These platforms assess transcriptomic tumor landscapes
to calculate a patient's 10-year risk of distant recurrence, dropping chemotherapy
recommendations by 12% to 75% in real-world clinical cohorts [Nalbant et al., 2025; Sinn et al.,
2013]. While these tests demonstrate robust prognostic utility in predicting distant metastasis,
their predictive benefit varies sharply by physiological factors [Nalbant et al., 2025]. For
instance, prospective data from the RxPONDER and TAILORx trials indicate that while post-
menopausal lymph-node-positive (LN+) patients with low genomic risk scores derive no
chemotherapy benefit, pre-menopausal women with identical low scores still experience
significant therapeutic advantages [Nalbant et al., 2025; Siegelmann-Danieli et al., 2013].
Despite their success, traditional assays present distinct clinical limitations in scoring
methodology, demographic equity, and biological scope [Gao et al., 2023; Kim et al., 2021; van
den Broek et al., 2026]. Methodologically, using rigid, dichotomized "high vs. low" cutoffs
severely limits clinical utility compared to utilizing continuous risk scores within integrated
algorithms [van den Broek et al., 2026]. Furthermore, current standardized risk thresholds (e.g.,
Recurrence Score >25) may inappropriately withhold chemotherapy from diverse populations;
recent survival modeling demonstrates distinct racial variations, showing that White, Black, and
Asian women exhibit vastly different chemotherapy sensitivity thresholds [Gao et al., 2023].
Finally, standard assays focus almost exclusively on HR+/HER2− early-stage tumors,
completely omitting host immune microenvironment dynamics and germline-somatic alterations
that drive therapeutic evasion [Kim et al., 2021; Tan et al., 2018; Wokolorczyk et al., 2024].
To bridge these gaps, cutting-edge precision oncology is transitioning toward next-generation
sequencing (NGS) panels, immune-cell profiling, and evolutionary genomics [Kim et al., 2021;
Moon et al., 2024; Tan et al., 2018]. Emerging 179-gene NGS panels like OncoFREE
demonstrate superior performance in catching high-risk metastatic profiles in young patients
(≤50 years) missed by traditional assays [Moon et al., 2024]. Concurrently, novel immune
prognostic indices tracking tumor-infiltrating lymphocytes (TILs) and specific immunity gene
expressions (such as TRAT1 and CTLA4) successfully predict disease-free survival across
multiple molecular subtypes [Kim et al., 2021; Tan et al., 2018]. Upstream, genome-wide
association studies are uncovering germline variations in "driver kinase" loci (e.g., EPHB1,
CDKL2) that influence early-age carcinogenesis [Wokolorczyk et al., 2024]. At the metastatic
site, deep whole-genome sequencing confirms that recurrent somatic single nucleotide variants
and copy number variations drive the evolutionary resistance that renders secondary lesions
refractory to treatment [Borst et al., 2026].
This review paper aims to evaluate how genomic signatures clarify breast cancer recurrence and
treatment resistance subtypes. Specifically, this paper will synthesize global clinical data on
standard multigene assay implementation, examine the clinical necessity of calibrating
continuous scores to account for racial and age-based variations, and explore how expanded
NGS panels, microenvironment immune signatures, and metastatic somatic evolution profiles
can be integrated to refine long-term risk assessment.
📚 Bibliography (The mapped reference papers)
1. [Siegelmann-Danieli et al., 2013]: The impact of the Oncotype DX Recurrence Score on
treatment decisions and clinical outcomes... Maccabi Healthcare Services.
2. [Gao et al., 2023]: Predicting Chemotherapy Benefit across Different Races in Early-
Stage Breast Cancer (SEER-Oncotype cohort).
3. [Borst et al., 2026]: Association between pathological characteristics and clinical
outcomes in Hungarian breast cancer cohorts.
4. [Taylor et al., 2024]: Navigating precision: the crucial role of next-generation
sequencing recurrence risk assessment in HR+/HER2− breast cancer.
5. [Nalbant et al., 2025]: Gene expression profiling tests to guide adjuvant chemotherapy
decisions in lymph node-positive early breast cancer: a systematic review.
6. [van den Broek et al., 2026]: Guiding treatment decisions in early breast cancer: A
model-based comparison of the OncotypeDX and MammaPrint tests.
7. [Sinn et al., 2013]: Multigene Assays for Classification, Prognosis, and Prediction in
Breast Cancer: a Critical Review.
8. [Kim et al., 2021]: A novel immune prognostic index for stratification of high-risk
patients with early breast cancer.
9. [Moon et al., 2024]: Evaluation of OncoFREE next-generation sequencing 179-gene
assay versus Oncotype DX Recurrence Score.
10. [Tan et al., 2018]: Tumor-infiltrating lymphocytes (TIL) and a 72-gene immunity panel
prediction of outcome.
11. [Wokolorczyk et al., 2024]: Germline distribution of somatic gene labels within breast
cancer risk GWAS (Poland population study).
12. [Taylor et al., 2024]: Somatic evolution, single nucleotide variants, and copy number
variations driving breast cancer metastasis.